A recent New York Times story described a new fad: "microdosing" GLP-1 anti-obesity drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). I was asked to discuss the topic on ...
A new approach to treat rosacea and other inflammatory skin conditions could be on the horizon, according to a University of ...
Studies suggest that semaglutide reduces heart attack and stroke and may curb addiction and more. Scientists reflect on the future of GLP-1 drugs beyond weight loss.
GLP-1 agonists substantially slowed kidney deterioration and failure, independent of diabetes status. The most extensive and ...
The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.
Hosted on MSN2d
Ozempic: What It Is, Uses, Side Effects & Drug InteractionsOzempic (semaglutide) is an injectable, prescription-only medication that suppresses appetite and slows down digestion. Here, ...
A new drug dubbed the “King Kong” of weight-loss jabs will be available in Ireland early next year, it was confirmed ...
NJBIZ, New Jersey’s leading business journal, provides 24/7 business news coverage and events honoring top business professionals.
Wegovy, Ozempic, Mounjaro and retatrutide – the ‘miracle’ drugs are booming. We assess whether they’re safe and how they ...
US: Sharing the topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial, Eli Lilly and Company ...
Zepbound® (tirzepatide) provided a 47% greater relative weight loss compared to Wegovy® (semaglutide). On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy.i At 72 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback